MedTrace Logo

Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma

NCT00327314 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2006-12-28

No results posted yet for this study

Summary

The protocol aims at reducing transplant toxicity and mortality in patients with multiple myeloma.

Conditions

Interventions

PROCEDURE

Transplantation

PROCEDURE

Hematopoietic cell transplantation

Sponsors & Collaborators

  • Azienda Ospedaliera San Giovanni Battista

    lead OTHER

Principal Investigators

  • Benedetto Bruno, MD, PhD · Divisione di Ematologia _ Azienda Ospedaliera S G Battista di Torino

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Completion
2006-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00327314 on ClinicalTrials.gov